Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365558 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02365558: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT02365558 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02365558, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of increased stomach pH on how much evacetrapib is found in the blood stream and how long the body takes to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected. There are two parts to the study. Participation in both parts will be required. The study will last approximately 30 days, not including screening.
Interventions
- DRUG Omeprazole
- DRUG Evacetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
What the finished NCT02365558 record still lists
NCT02365558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Omeprazole is the first listed.
NCT02365558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02365558 about?
NCT02365558 is a clinical study titled "A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants". The purpose of this study is to evaluate the effect of increased stomach pH on how much evacetrapib is found in the blood stream and how long the body takes to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected. There are two p...
What is the current status of trial NCT02365558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2015-01. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02365558?
The interventions under investigation include: Omeprazole (DRUG), Evacetrapib (DRUG).
Who is sponsoring clinical trial NCT02365558?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02365558's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia